A post-marketing surveillance study of tolperisone [MYOTOP-150]: It's use in the general clinical practice in India

Journal of Clinical and Diagnostic Research

Volumn 5, Issue 3, 2011, Pages 561-565

  Dewan, Bhupesh ^a   Philipose, Nisha ^a  

^a Zuventus Healthcare Ltd   (India)

Author keywords

Muscle relaxant; Muscle spasm; Muscle sprain; Spasticity; Tolperisone

Indexed keywords

MYOTOP 150; TOLPERISONE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DROWSINESS; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG USE; FEMALE; GENERAL PRACTICE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MUSCLE SPASM; NAUSEA; OUTCOME ASSESSMENT; PRESCRIPTION; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; SEDATION; SIDE EFFECT; SPASTICITY; TREATMENT DURATION; VERTIGO; XEROSTOMIA;

EID: 79959305523     PISSN: None     EISSN: 0973709X     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Quasthoff S, Möckel C, Zieglgänsberger W, Schreibmayer W. Tolperisone: a typical representative of a class of centrally acting muscle relaxants with less sedative side effects. CNS Neurosci Ther. 2008 Summer;14(2):107-19.
2. Tolperisone. In: Sweetman SC, editor. Martindale- The Complete Drug Reference. 36th ed. London: Pharmaceutical Press; 2009. p. 1899.
3. Girish MB, Bhuvana K, Sarala N, Kumar TN. Tolperisone. J Anaesth Clin Pharmacol 2010; 26(3): 363-364.
4. Vora A. Tolperisone. J Assoc Physicians India. 2010 Feb;58:127-8.
5. Pratzel HG, Alken RG, Ramm S. Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo-controlled double-blind trial. Pain. 1996 Oct;67(2-3):417-25.
6. Kocsis P, Farkas S, Fodor L, Bielik N, Thán M, Kolok S, et al. Tolperisone-type drugs inhibit spinal reflexes via blockade of voltagegated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
7. Furuta Y, Yoshikawa A. Reversible adrenergic alpha-receptor blocking action of 2,4'-dimethyl-3-piperidino-propiophenone (tolperisone). Jpn J Pharmacol. 1976 Oct;26(5):543-50.
8. Chernysheva TV, Bagirova GG. Midocalm in complex therapy of chronic low back pain syndrome. Klin Med (Mosk). 2005;83(11):45-9.
9. Stamenova P, Koytchev R, Kuhn K, Hansen C, Horvath F, Ramm S, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. Eur J Neurol. 2005 Jun;12(6):453-61.
10. Solov'eva AD, Akarachkova ES, Gordeev SA. A study of mydocalm efficiency in the treatment of chronic headache of tension. Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(12):13-7.
11. Alibekov IM. Treatment of neurosensory hypoacusis of antibiotic and non-antibiotic etiology with mydocalm and nootropil: comparison of efficacy. Vestn Otorinolaringol. 1997;(4):20-3.
12. Sásdi A. Mydocalm treatment of muscular and vascular complaints accompanying climacterics. Ther Hung. 1992;40(2):83-5.
13. Inovay J, Katona J. Several years of observation with Tolperisone in the treatment of lockjaw. Ther Hung. 1991;39(4):185-7.
14. Haque A, Hossain M, Khan JK, Kuo YH, Lambein F, De Reuck J. New findings and symptomatic treatment for neurolathyrism, a motor neuron disease occurring in North West Bangladesh. Paraplegia. 1994 Mar;32(3):193-5.
15. Gelber DA, Good DC, Dromerick A, Sergay S, Richardson M. Openlabel dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke. Stroke. 2001 Aug;32(8):1841-6.
16. Browning R, Jackson JL, O'Malley PG. Cyclobenzaprine and back pain: a meta-analysis. Arch Intern Med. 2001 Jul 9;161(13):1613-20.
17. Gracies JM, Nance P, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Muscle Nerve Suppl. 1997;6:S92-120.
18. Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004 Aug;28(2):140-75.
19. Dulin J, Kovács L, Ramm S, Horvath F, Ebeling L, Kohnen R. Evaluation of sedative effects of single and repeated doses of 50 mg and 150 mg tolperisone hydrochloride. Results of a prospective, randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry. 1998 Jul;31(4):137-42.